Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: Importance of appropriate replacement of basal insulin and time-interval injection-meal

Diabetic Medicine

Volumn 15, Issue 7, 1998, Pages 592-600

  Del Sindaco, P ^a   Ciofetta, M ^a   Lalli, C ^a   Perriello, G ^a   Pampanelli, S ^a   Torlone, E ^a   Brunetti, P ^a   Bolli, G B ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Hypoglycaemia; Insulin analogues; Intensive insulin therapy; Intermediate acting insulin; Lispro; Type 1 diabetes mellitus

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN LISPRO;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FOOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; SOLUBILITY; TIME FACTORS;

EID: 0031875070     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199807)15:7<592::AID-DIA625>3.0.CO;2-J     Document Type: Article

References (29)

1. Shade S, Santiago JV, Skyler JS, Rizza RA, eds. Intensive Insulin Therapy. Amsterdam: Excerpta Medica, 1983.
2. Bolli GB. The pharmacokinetic basis of insulin therapy. Diab Res Clin Prac 1989; 6: S3-S16.
3. Pampanelli S, Fanelli C, Lalli C, Ciofetta M, Del Sindaco P, Lepore M, et al. Long-term intensive insulin therapy: effects of HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and unawareness of hypoglycaemia. Diabetologia 1996; 39: 677-686.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Bolli GB. From physiology of glucose counterregulation to prevention of hypoglycaemia in Type 1 diabetes mellitus. Diab Nutr Metab 1990 ; 3: 333-349.
6. Dimitriadis G, Gerich J. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-377.
7. Pampanelli S, Torlone E, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analogue in IDDM of short duration with residual pancreatic γ-cell function. Diabetes Care 1995; 18: 1452-1459.
8. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)] human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
9. Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI, Parving HH. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 1995; 38: 592-598.
10. Anderson JH, Brunelle R, Koivisto VA, Pfuetzner A, Trautman M, Vignati L, et al. Insulin analogue treatment reduces postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients. Diabetes 1997; 46: 265-270.
11. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with Type 1 diabetes. Diabetic Med 1996; 13: 47-52.
12. Pfuetzner A, Kuestner E, Forst T, Schulze-Sthleppinghoff B, Tratuman M, Haslbeck M, et al. Intensive insulin therapy with insulin lispro in patients with Type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol 1996; 104: 25-30.
13. Rowe R, Anderson JH, Gale E. A double-blind comparison of insulin Lispro and regular insulin in patients on a multiple injection regimen. Diabetes 1996; 45 (suppl 2): 71A.
14. Jacobs MAJM, Keulen ETP, Kanc K, Casteleijn S, Scheffer P, Deville W, et al. Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM patients. Diabetes Care 1997; 20: 1279-1286.
15. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson J, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997; 20: 1827-1832.
16. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-720.
17. Tuominen JA, Karonen S-L, Melamies L, Bolli G, Koivisto VA. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995; 38: 106-111.
18. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, et al. Effect of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945-952.
19. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies towards improved control during insulin lispro therapy: importance of basal insulin. Diabetes Care 1997; 20: 1287-1289.
20. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack TR. Insulin Lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440-443.
21. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J 1982; 285: 916-918.
22. Bolli GB, Perriello G, Fanelli C, De Feo. Nocturnal blood glucose control in Type 1 diabetes mellitus. Diabetes Care 1993; 16 (suppl 3): 71-89.
23. Zar J. Biostatistical Analysis. Englewood Cliffs: Prentice Hall, 1984.
24. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997; 337: 176-103.
25. Ebeling P, Jansson P-A, Smith U, Conget I, Coves MJ, Gomis R, et al. Optimal combination of insulin lispro and basal insulin improves glycemic control in IDDM. Diabetologia 1997; 40 (suppl 1): A351.
26. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
27. Lean MEJ, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J 1985; 290: 105-108.
28. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokineties. Diabetes Care 1984; 3: 188-199.
29. Rosenherg WM, Sackett DL. On the need for evidence-based medicine. Therapie 1996; 51: 212-217.